1308 related articles for article (PubMed ID: 32325252)
1. COVID-19 pathophysiology: A review.
Yuki K; Fujiogi M; Koutsogiannaki S
Clin Immunol; 2020 Jun; 215():108427. PubMed ID: 32325252
[TBL] [Abstract][Full Text] [Related]
2. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
3. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
4. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.
Sawalha AH; Zhao M; Coit P; Lu Q
Clin Immunol; 2020 Jun; 215():108410. PubMed ID: 32276140
[TBL] [Abstract][Full Text] [Related]
6. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
7. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
8. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
9. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.
Saha A; Saha B
Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective.
Sironi M; Hasnain SE; Rosenthal B; Phan T; Luciani F; Shaw MA; Sallum MA; Mirhashemi ME; Morand S; González-Candelas F;
Infect Genet Evol; 2020 Oct; 84():104384. PubMed ID: 32473976
[TBL] [Abstract][Full Text] [Related]
11. Cancer therapy and treatments during COVID-19 era.
Akula SM; Abrams SL; Steelman LS; Candido S; Libra M; Lerpiriyapong K; Cocco L; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Blalock WL; Piazzi M; Montalto G; Cervello M; Notarbartolo M; Basecke J; McCubrey JA
Adv Biol Regul; 2020 Aug; 77():100739. PubMed ID: 32773105
[TBL] [Abstract][Full Text] [Related]
12. The Immune Response and Immunopathology of COVID-19.
Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
Front Immunol; 2020; 11():2037. PubMed ID: 32983152
[TBL] [Abstract][Full Text] [Related]
13. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells.
Azizi SA; Azizi SA
J Neurovirol; 2020 Oct; 26(5):631-641. PubMed ID: 32876900
[TBL] [Abstract][Full Text] [Related]
14. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Immunology and treatment options.
Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
[TBL] [Abstract][Full Text] [Related]
16. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
Tan HW; Xu YM; Lau ATY
Rev Med Virol; 2020 Sep; 30(5):e2122. PubMed ID: 32602627
[TBL] [Abstract][Full Text] [Related]
18. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H; Pillat MM
Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
20. Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.
Rossi GA; Sacco O; Mancino E; Cristiani L; Midulla F
Infection; 2020 Oct; 48(5):665-669. PubMed ID: 32737833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
